Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02808208
Recruitment Status : Recruiting
First Posted : June 21, 2016
Last Update Posted : February 6, 2019
Information provided by (Responsible Party):
Sanjay Misra, M.D., Mayo Clinic

Brief Summary:
The aim of this phase 1 study is to determine the role of autologous adipose derived mesenchymal stem cells in the reduction of hemodialysis arteriovenous fistula failure when applied during the time of surgical creation.

Condition or disease Intervention/treatment Phase
End Stage Renal Disease (ESRD) Vascular Access Complication Biological: Adipose Derived Mesenchymal Stem Cells (AMSC) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
Actual Study Start Date : June 7, 2017
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis Fistulas

Arm Intervention/treatment
Experimental: Group 1 AMSC Treatment
Patients have tissue biopsy and Adipose Derived Mesenchymal Stem Cells (AMSC) treatment.
Biological: Adipose Derived Mesenchymal Stem Cells (AMSC)
This group will receive Autologous stem cells derived from own fat biopsy.

No Intervention: Group 2 No Treatment
Patients receive standard of care.

Primary Outcome Measures :
  1. Hemodialysis outflow vein diameter [ Time Frame: Baseline to 12 months after AVF creation ]
    Diameter of outflow vein by ultrasound

Secondary Outcome Measures :
  1. Hemodialysis AVF Blood flow [ Time Frame: Baseline to 12 months after AVF creation ]
    blood flow by ultrasound or dialysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Patient between 18 and 85 years old
  • Patient currently on hemodialysis or pre-dialysis and planned creation of an upper extremity AV fistula with suitable anatomy
  • Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures
  • Life expectancy of at least 24 months

Exclusion Criteria

  • Malignancy or treatment for malignancy within the previous 6 months
  • Immunodeficiency including AIDS / HIV or Active autoimmune disease
  • Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous intravascular thrombotic events
  • Pregnancy or breast feeding
  • Treatment with any investigational drug/ device within 60 days prior to study entry or Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs and the AVF
  • Employees of the sponsor or patients who are employees or relatives of the investigator
  • History of failed organ transplant on immunosuppression

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02808208

Layout table for location contacts
Contact: Lori Johnson 507-266-0899
Contact: Matthew Hoplin 507-293-0947

Layout table for location information
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Sanjay Misra, M.D. Mayo Clinic

Layout table for additonal information
Responsible Party: Sanjay Misra, M.D., M.D., Mayo Clinic Identifier: NCT02808208    
Other Study ID Numbers: 15-009053
First Posted: June 21, 2016    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Arteriovenous Fistula
Urologic Diseases
Pathological Conditions, Anatomical
Arteriovenous Malformations
Vascular Malformations
Cardiovascular Abnormalities
Cardiovascular Diseases
Vascular Fistula
Vascular Diseases
Congenital Abnormalities